

				DISEASE	
<u>60264817</u>	Not Issued	020	01/26/2001	NEW STRATEGIES FOR THE DISCOVERY AND VALIDATION OF NOVEL DRUG TARGETS USING GENETICALLY ALTERED MICE	COLLEN, DESIRE
<u>60299192</u>	Not Issued	020	06/20/2001	STIMULATION OF VASCULARIZATION WITH VEGF-B	COLLEN, DESIRE

Inventor Search Completed: No Records to Display.

	Last Name	First Name
Search Another:	<input type="text" value="collen"/>	<input type="text" value="desire"/>
Inventor	<input type="button" value="Search"/>	

(To go back use Back button on your browser toolbar.)

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

=> d his

(FILE 'HOME' ENTERED AT 10:19:32 ON 29 APR 2002)

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 10:19:56 ON 29 APR 2002

SEA STAPHYLOKINAS?

118 FILE ADISALERTS
3 FILE ADISINSIGHT
11 FILE ADISNEWS
2 FILE AGRICOLA
4 FILE ANABSTR
11 FILE BIOBUSINESS
13 FILE BIOCOMMERCE
298 FILE BIOSIS
68 FILE BIOTECHABS
68 FILE BIOTECHDS
239 FILE BIOTECHNO
18 FILE CABA
12 FILE CANCERLIT
432 FILE CAPLUS
16 FILE CEABA-VTB
4 FILE CIN
11 FILE CONFSCI
14 FILE DDFB
125 FILE DDFU
271 FILE DGENE
14 FILE DRUGB
2 FILE DRUGNL
127 FILE DRUGU
2 FILE DRUGUPDATES
2 FILE EMBAL
339 FILE EMBASE
89 FILE ESBIODBASE
1 FILE FROSTI
10 FILE FSTA
72 FILE GENBANK
1 FILE HEALSAFE
16 FILE IFIPAT
22 FILE JICST-EPLUS
67 FILE LIFESCI
221 FILE MEDLINE
6 FILE NTIS
127 FILE PASCAL
5 FILE PHAR
7 FILE PHIN
12 FILE PROMT
289 FILE SCISEARCH
170 FILE TOXCENTER
67 FILE USPATFULL
46 FILE WPIDS
46 FILE WPINDEX
1 FILE IPA
1 FILE NAPRALERT
12 FILE NLDB

L1 QUE STAPHYLOKINAS?

FILE 'CAPLUS, EMBASE, BIOSIS, SCISEARCH, DGENE, BIOTECHNO, MEDLINE, TOXCENTER, DRUGU, PASCAL, ADISALERTS, ESBIODBASE, GENBANK, BIOTECHDS, LIFESCI, USPATFULL, WPIDS, JICST-EPLUS, CABA, CEABA-VTB, IFIPAT' ENTERED AT 10:20:58 ON 29 APR 2002

L2 1018 S STAPHYLOKINAS? AND SAK?

L3 432 DUP REM L2 (586 DUPLICATES REMOVED)

L4 191 S L3 AND (REDUC? (P) IMMUNOGEN?)

L5 191 FOCUS L4 1-
L6 84 S L4 AND POLYETHYLEN?

Welcome to STN International! Enter x:x

LOGINID:sssptal652dmr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:19:32 ON 29 APR 2002

=> index bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...'
ENTERED AT 10:19:56 ON 29 APR 2002

63 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s staphylokinas?

118	FILE ADISALERTS
3	FILE ADISINSIGHT
11	FILE ADISNEWS
2	FILE AGRICOLA
4	FILE ANABSTR
11	FILE BIOBUSINESS
13	FILE BIOCOMMERCE
298	FILE BIOSIS
68	FILE BIOTECHABS
68	FILE BIOTECHDS
239	FILE BIOTECHNO
18	FILE CABA
12	FILE CANCERLIT
432	FILE CAPLUS
16	FILE CEABA-VTB
4	FILE CIN
11	FILE CONFSCI
14	FILE DDFB
125	FILE DDFU
271	FILE DGENE
14	FILE DRUGB
2	FILE DRUGNL
127	FILE DRUGU
2	FILE DRUGUPDATES
2	FILE EMBAL
339	FILE EMBASE
89	FILE ESBIODBASE
1	FILE FROSTI
10	FILE FSTA

37 FILES SEARCHED...

72	FILE GENBANK
1	FILE HEALSAFE
16	FILE IFIPAT
22	FILE JICST-EPLUS
67	FILE LIFESCI
221	FILE MEDLINE
6	FILE NTIS
127	FILE PASCAL
5	FILE PHAR
7	FILE PHIN
12	FILE PROMT
289	FILE SCISEARCH
170	FILE TOXCENTER
67	FILE USPATFULL
46	FILE WPIDS
46	FILE WPINDEX
1	FILE IPA
1	FILE NAPRALERT
12	FILE NLDB

48 FILES HAVE ONE OR MORE ANSWERS, 63 FILES SEARCHED IN STNINDEX

L1 QUE STAPHYLOKINAS?

=> d rank

F1	432	CAPLUS
F2	339	EMBASE
F3	298	BIOSIS
F4	289	SCISEARCH
F5	271	DGENE
F6	239	BIOTECHNO
F7	221	MEDLINE
F8	170	TOXCENTER
F9	127	DRUGU
F10	127	PASCAL
F11	125	DDFU
F12	118	ADISALERTS
F13	89	ESBIOBASE
F14	72	GENBANK
F15	68	BIOTECHABS
F16	68	BIOTECHDS
F17	67	LIFESCI
F18	67	USPATFULL
F19	46	WPIDS
F20	46	WPINDEX
F21	22	JICST-EPLUS
F22	18	CABA
F23	16	CEABA-VTB
F24	16	IFIPAT
F25	14	DDFB
F26	14	DRUGB
F27	13	BIOCOMMERCE
F28	12	CANCERLIT
F29	12	PROMT
F30	12	NLDB
F31	11	ADISNEWS
F32	11	BIOBUSINESS
F33	11	CONFSCI
F34	10	FSTA
F35	7	PHIN
F36	6	NTIS
F37	5	PHAR
F38	4	ANABSTR
F39	4	CIN
F40	3	ADISINSIGHT
F41	2	AGRICOLA
F42	2	DRUGNL
F43	2	DRUGUPDATES
F44	2	EMBAL
F45	1	FROSTI
F46	1	HEALSAFE
F47	1	IPA
F48	1	NAPRALERT

=> file f1-f25

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

1.06

1.27

FILE 'CAPLUS' ENTERED AT 10:20:58 ON 29 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'DGENE' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOTECHNO' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 10:20:58 ON 29 APR 2002

FILE 'TOXCENTER' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 ACS

FILE 'DRUGU' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'PASCAL' ENTERED AT 10:20:58 ON 29 APR 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'ADISALERTS' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ESBIOBASE' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'GENBANK' ENTERED AT 10:20:58 ON 29 APR 2002

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'LIFESCI' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 10:20:58 ON 29 APR 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'JICST-EPLUS' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'CABA' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CEABA-VTB' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (c) 2002 DECHEMA eV

FILE 'IFIPAT' ENTERED AT 10:20:58 ON 29 APR 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'DDFB' ACCESS NOT AUTHORIZED

=> s staphylokinas? and sak?
L2 1018 STAPHYLOKINAS? AND SAK?

=> dup rem l2
DUPLICATE IS NOT AVAILABLE IN 'DGENE, GENBANK'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 99% COMPLETE FOR L2
PROCESSING COMPLETED FOR L2
L3 432 DUP REM L2 (586 DUPLICATES REMOVED)

=> s l3 and (reduc? (p) immunogen?)
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'REDUC? (P) IMMUNOGEN'
8 FILES SEARCHED...
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'REDUC? (P) IMMUNOGEN'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'REDUC? (P) IMMUNOGEN'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'REDUC? (P) IMMUNOGEN'
14 FILES SEARCHED...
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'REDUC? (P) IMMUNOGEN'
20 FILES SEARCHED...
L4 191 L3 AND (REDUC? (P) IMMUNOGEN?)

=> focus l4
PROCESSING COMPLETED FOR L4
L5 191 FOCUS L4 1-

=> s l4 and polyethylen?
L6 84 L4 AND POLYETHYLEN?

=> d ti l6 1-84

L6 ANSWER 1 OF 84 CAPLUS COPYRIGHT 2002 ACS
TI **Polyethylene** glycol-derivatized cysteine-substitution variants
of recombinant **staphylokinase** for single-bolus treatment of
acute myocardial infarction

L6 ANSWER 2 OF 84 CAPLUS COPYRIGHT 2002 ACS
TI Pharmacokinetic and thrombolytic properties of cysteine-linked
polyethylene glycol derivatives of **staphylokinase**

L6 ANSWER 3 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 4 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 5 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**

immunogenicity, used for, e.g. treatment of arterial thrombosis

- L6 ANSWER 6 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 7 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 8 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 9 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 10 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 11 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 12 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 13 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 14 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 15 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 16 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 17 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 18 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 19 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 20 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis
- L6 ANSWER 21 OF 84 DGENE (C) 2002 THOMSON DERWENT

TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 22 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 23 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 24 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 25 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 26 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 27 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 28 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 29 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 30 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 31 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 32 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 33 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 34 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 35 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 36 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
 immunogenicity, used for, e.g. treatment of arterial thrombosis

L6	ANSWER 37 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 38 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 39 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 40 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 41 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 42 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 43 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 44 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 45 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 46 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 47 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 48 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 49 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 50 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 51 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	
L6	ANSWER 52 OF 84	DGENE (C) 2002 THOMSON DERWENT
TI	Staphylokinase derivatives with reduced immunogenicity, used for, e.g. treatment of arterial thrombosis	

L6 ANSWER 53 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 54 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 55 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 56 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 57 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 58 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 59 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 60 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 61 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 62 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 63 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 64 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 65 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 66 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 67 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 68 OF 84 DGENE (C) 2002 THOMSON DERWENT
TI **Staphylokinase** derivatives with **reduced**

immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 69 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 70 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 71 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 72 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 73 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 74 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 75 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 76 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 77 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 78 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 79 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 80 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 81 OF 84 DGENE (C) 2002 THOMSON DERWENT
 TI **Staphylokinase** derivatives with **reduced**
immunogenicity, used for, e.g. treatment of arterial thrombosis

L6 ANSWER 82 OF 84 DRUGU COPYRIGHT 2002 THOMSON DERWENT
 TI Single bolus administration of **polyethylene** glycol-derived
 cysteine-substitution variants of recombinant **staphylokinase** in
 acute myocardial infarction.

L6 ANSWER 83 OF 84 USPATFULL
 TI Antibody conjugate compositions for selectively inhibiting VEGF

L6 ANSWER 84 OF 84 USPATFULL

TI Antibody compositions for selectively inhibiting VEGF

=> d 16 1,2,3,82,83,84

L6 ANSWER 1 OF 84 CAPLUS COPYRIGHT 2002 ACS

AN 2000:759538 CAPLUS

DN 134:336089

TI **Polyethylene** glycol-derivatized cysteine-substitution variants of recombinant **staphylokinase** for single-bolus treatment of acute myocardial infarction

AU Collen, Desire; Sinnaeve, Peter; Demarsin, Eddy; Moreau, Huberte; De Maeyer, Marc; Jespers, Laurent; Laroche, Yves; Van de Werf, Frans

CS Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Louvain, B-3000, Belg.

SO Circulation (2000), 102(15), 1766-1772

CODEN: CIRCAZ; ISSN: 0009-7322

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 84 CAPLUS COPYRIGHT 2002 ACS

AN 2000:80930 CAPLUS

DN 132:231482

TI Pharmacokinetic and thrombolytic properties of cysteine-linked **polyethylene** glycol derivatives of **staphylokinase**

AU Vanwetswinkel, Sophie; Plaisance, Stephane; Zhi-Yong, Zhang; Vanlinthout, Ingrid; Brepoels, Kathleen; Lasters, Ignace; Collen, Desire; Jespers, Laurent

CS Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute of Biotechnology, Louvain, B-3000, Belg.

SO Blood (2000), 95(3), 936-942

CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 84 DGENE (C) 2002 THOMSON DERWENT

AN AAY15033 Protein DGENE

TI **Staphylokinase** derivatives with **reduced immunogenicity**, used for, e.g. treatment of arterial thrombosis

IN Collen D J

PA (COLL-I) COLLEN D J.

(LEUV-N) LEUVEN RES & DEV VZW.

PI WO 9940198 A2 19990812 101p

AI WO 1999-EP748 19990204

PRAI EP 1998-200365 19980206

EP 1998-200323 19980204

DT Patent

LA English

OS 1999-508504 [42]

L6 ANSWER 82 OF 84 DRUGU COPYRIGHT 2002 THOMSON DERWENT

AN 2000-26168 DRUGU T P G

TI Single bolus administration of **polyethylene** glycol-derivatized cysteine-substitution variants of recombinant **staphylokinase** in acute myocardial infarction.

AU Sinnaeve P; Janssens S; Van de Werf F

LO Louvain, Belg.

SO Circulation (100, No. 18, Suppl., 650-51, 1999)
CODEN: CIRCAZ ISSN: 0009-7322
AV University Hospital Gasthuisberg, Leuven, Belgium.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L6 ANSWER 83 OF 84 USPATFULL
AN 2002:19060 USPATFULL
TI Antibody conjugate compositions for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6342221 B1 20020129
AI US 2000-561108 20000428 (9)
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS GRANTED
LN.CNT 10492
INCL INCLM: 424/178.100
INCLS: 424/130.100; 424/179.100; 424/181.100; 424/183.100; 424/193.100;
424/195.110; 424/001.490; 424/001.530; 424/009.300; 424/009.340;
424/009.600; 435/007.210; 435/069.100; 435/070.210; 435/810.000;
435/007.230; 435/007.100; 530/391.100; 530/391.300; 530/391.500;
530/391.700; 530/391.900
NCL NCLM: 424/178.100
NCLS: 424/001.490; 424/001.530; 424/009.300; 424/009.340; 424/009.600;
424/130.100; 424/179.100; 424/181.100; 424/183.100; 424/193.100;
424/195.110; 435/007.100; 435/007.210; 435/007.230; 435/069.100;
435/070.210; 435/810.000; 530/391.100; 530/391.300; 530/391.500;
530/391.700; 530/391.900
IC [7]
ICM: A61K039-44
ICS: A61K039-395
EXF 424/130.1; 424/133.1; 424/134.1; 424/135.1; 424/141.1; 424/142.1;
424/143.1; 424/178.1; 424/181.1; 424/183.1; 424/195.11; 424/179.1;
424/1.49; 424/1.53; 424/1.69; 424/193.1; 424/9.3; 424/9.34; 424/9.6;
530/387.1; 530/387.3; 530/388.1; 530/388.15; 530/388.22; 530/391.1;
530/391.3; 530/391.5; 530/391.7; 530/391.9; 530/809; 530/864; 530/865;
530/866; 435/7.1; 435/69.1; 435/70.21; 435/810; 435/7.21; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 84 OF 84 USPATFULL
AN 2002:19058 USPATFULL
TI Antibody compositions for selectively inhibiting VEGF
IN Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6342219 B1 20020129
AI US 2000-561500 20000428 (9)
PRAI US 1999-131432P 19990428 (60)
DT Utility
FS GRANTED
LN.CNT 10403
INCL INCLM: 424/145.100
INCLS: 424/133.100; 424/134.100; 424/135.100; 424/141.100; 424/142.100;
424/143.100; 435/069.100; 435/335.000; 435/810.000; 530/387.100;
530/387.300; 530/388.100; 530/388.150; 530/388.230; 530/391.100;
530/391.300; 530/391.500; 530/391.700; 530/809.000; 530/864.000;
530/865.000; 530/866.000

NCL NCLM: 424/145.100
 NCLS: 424/133.100; 424/134.100; 424/135.100; 424/141.100; 424/142.100;
 424/143.100; 435/069.100; 435/335.000; 435/810.000; 530/387.100;
 530/387.300; 530/388.100; 530/388.150; 530/388.230; 530/391.100;
 530/391.300; 530/391.500; 530/391.700; 530/809.000; 530/864.000;
 530/865.000; 530/866.000

IC [7]
 ICM: A61K039-395
 ICS: C12P021-08; C07K016-00

EXF 424/130.1; 424/133.1; 424/134.1; 424/135.1; 424/141.1; 424/142.1;
 424/143.1; 424/145.1; 435/810; 435/69.1; 435/335; 530/387.1; 530/387.3;
 530/388.1; 530/388.15; 530/388.23; 530/391.1; 530/391.3; 530/391.5;
 530/391.7; 530/809; 530/864; 530/865; 530/866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:19:32 ON 29 APR 2002)

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI,
 BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA,
 CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB,
 DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 10:19:56 ON
 29 APR 2002

SEA STAPHYLOKINAS?

 118 FILE ADISALERTS
 3 FILE ADISINSIGHT
 11 FILE ADISNEWS
 2 FILE AGRICOLA
 4 FILE ANABSTR
 11 FILE BIOBUSINESS
 13 FILE BIOCOMMERCE
 298 FILE BIOSIS
 68 FILE BIOTECHABS
 68 FILE BIOTECHDS
 239 FILE BIOTECHNO
 18 FILE CABA
 12 FILE CANCERLIT
 432 FILE CAPLUS
 16 FILE CEABA-VTB
 4 FILE CIN
 11 FILE CONFSCI
 14 FILE DDFB
 125 FILE DDFU
 271 FILE DGENE
 14 FILE DRUGB
 2 FILE DRUGNL
 127 FILE DRUGU
 2 FILE DRUGUPDATES
 2 FILE EMBAL
 339 FILE EMBASE
 89 FILE ESBIODASE
 1 FILE FROSTI
 10 FILE FSTA
 72 FILE GENBANK
 1 FILE HEALSAFE
 16 FILE IFIPAT
 22 FILE JICST-EPLUS
 67 FILE LIFESCI
 221 FILE MEDLINE
 6 FILE NTIS

127 FILE PASCAL
 5 FILE PHAR
 7 FILE PHIN
 12 FILE PROMT
 289 FILE SCISEARCH
 170 FILE TOXCENTER
 67 FILE USPATFULL
 46 FILE WPIDS
 46 FILE WPINDEX
 1 FILE IPA
 1 FILE NAPRALERT
 12 FILE NLDB

L1 QUE STAPHYLOKINAS?

FILE 'CAPLUS, EMBASE, BIOSIS, SCISEARCH, DGENE, BIOTECHNO, MEDLINE,
 TOXCENTER, DRUGU, PASCAL, ADISALERTS, ESBIODBASE, GENBANK, BIOTECHDS,
 LIFESCI, USPATFULL, WPIDS, JICST-EPLUS, CABA, CEABA-VTB, IFIPAT' ENTERED
 AT 10:20:58 ON 29 APR 2002

L2 1018 S STAPHYLOKINAS? AND SAK?
 L3 432 DUP REM L2 (586 DUPLICATES REMOVED)
 L4 191 S L3 AND (REDUC? (P) IMMUNOGEN?)
 L5 191 FOCUS L4 1-
 L6 84 S L4 AND POLYETHYLEN?

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
47.00	48.27

FULL ESTIMATED COST

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:28:44 ON 29 APR 2002